Clinical trials: Interstitial Lung Fibrosis
Idiopathic Pulmonary Fibrosis, Cardiac Fibrosis
Cardiovascular Fibrosis in Idiopathic Pulmonary Fibrosis
Fibroproliferative diseases, including pulmonary, cardiac and vascular fibrosis share common pathogenetic mechanisms. Furthermore, cardiovascular comorbidities are frequently found in patients with IPF.
- Conditions
- Idiopathic Pulmonary Fibrosis, Cardiac Fibrosis, Arterial Fibrosis
- Trial name
- CardioIPF (NCT04177251)
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- San Gerardo Hospital
Idiopathic Pulmonary Fibrosis
Quality of Life in IPF - Patient and Physician Perceptions
This study aims to evaluate the differences between patient's and their physicians' perception of quality of life and the effect of disease severity and co-morbidities.
- Trial name
- QUALY-IPF-PPP (NCT04148157)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Washington
Fibrosis Lung, Systemic Sclerosis
Identifying Unique Pathogenic Macrophages in Systemic Sclerosis-ILD
Alveolar macrophages isolated from bronchoalveolar lavage (BAL) fluid from systemic sclerosis (SSc) patients with clinically significant lung fibrosis will be studied at baseline and at 6 months after enrollment to assess…
- Trial name
- NCT03438032
- Testing
- Bronchoscopy with lavage
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Idiopathic Pulmonary Fibrosis
A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
This study is open to adults with idiopathic pulmonary fibrosis (IPF) who are at least 40 years old. People taking standard medicines for IPF, including antifibrotic medicines, can continue taking them throughout the study.
- Trial name
- NCT04419506
- Testing
- BI 1015550
- Where
- 75 sites in United States, Argentina and 20 more
- Volunteers
- 147 people
- Sponsor
- Boehringer Ingelheim
Interstitial Lung Diseases
Advanced Mutidimensional and Ultra High Resolution Computed Tomography to Inspect Cardiopulmonary Involvement in Progressive Fibrosing Interstitial Lung Diseases
Interstitial lung diseases (ILDs) are common chronic disease characterized by high mortality and morbidity, also linked to cardiovascular implication.
- Trial name
- AMICI-ILD (NCT06537934)
- Where
- Italy
- Volunteers
- 123 people
- Sponsor
- IRCCS San Raffaele
Idiopathic Pulmonary Fibrosis
Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis
The purpose of this study was to investigate the safety, tolerability and efficacy of VAY736 as potential therapy for the treatment of idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT03287414
- Testing
- VAY736, Standard of Care (SoC)
- Where
- 16 sites in United States, Canada and 4 more
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Dyspnea, Lung Diseases
Effects of Automated Oxygen Titration Alone or With High Flow Nasal Therapy on Dyspnea and Exercise Tolerance
The main purpose of this study is to evaluate the effects of automated oxygen administration (FreeO2 system) alone or with high-flow oxygen on dyspnea and exercise tolerance in people with desaturating chronic lung disease…
- Conditions
- Dyspnea, Lung Diseases, Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
- Trial name
- NCT05267418
- Testing
- Automated nasal O2 titration with FreeO2
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Laval University
Pulmonary Fibrosis
Exhaled Breath Analysis Using eNose Technology as a Biomarker for Diagnosis and Disease Progression in Fibrotic ILD
The ILDnose study a multinational, multicenter, prospective, longitudinal study in outpatients with pulmonary fibrosis. The aim is to assess the accuracy of eNose technology as diagnostic tool for diagnosis and differentiation…
- Trial name
- ILDnose (NCT04680832)
- Testing
- Electronic nose
- Where
- 5 sites in Australia, France and 3 more
- Volunteers
- 600 people
- Sponsor
- Erasmus Medical Center
Idiopathic Pulmonary Fibrosis
A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
The aims of the study are to assess safety, tolerability, the pharmacokinetic profile, and the pharmacodynamic profile of multiple doses of PRM-151 administered IV to IPF patients.
- Trial name
- PRM151F-12GL (NCT01254409)
- Testing
- PRM-151
- Where
- 3 sites in United States, Netherlands
- Volunteers
- 21 people
- Sponsor
- Hoffmann-La Roche
Idiopathic Pulmonary Fibrosis, Idiopathic Interstitial Pneumonia
Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank
Born out of the European Union 7th Framework Programme funded project European IPF Network (eurIPFnet), the European IPF Registry (eurIPFreg) has become Europe's leading database of longitudinal data from IPF patients, including…
- Conditions
- Idiopathic Pulmonary Fibrosis, Idiopathic Interstitial Pneumonia, Interstitial Lung Diseases, Diffuse Parenchymal Lung Diseases
- Trial name
- eurIPFreg (NCT02951416)
- Testing
- patient registry (observation and biomaterial sampling)
- Where
- 7 sites in Austria, France and 3 more
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Andreas Guenther
Idiopathic Pulmonary Fibrosis
Cough Reduction in IPF With Nalbuphine ER
The main purpose of the study is to evaluate the effect of NAL ER on 24-hour cough frequency using objective digital cough monitoring and to assess safety and tolerability of NAL ER.
- Trial name
- CORAL (NCT05964335)
- Testing
- NAL ER
- Where
- 59 sites in Australia, Canada and 8 more
- Volunteers
- 165 people
- Sponsor
- Trevi Therapeutics
Idiopathic Pulmonary Fibrosis
Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
The primary purpose of this multi-center, double-blind, placebo-controlled, dose-ranging Phase I study is to assess the safety of a purified from green tea, EGCG, in patients with idiopathic pulmonary fibrosis (IPF) as a…
- Trial name
- NCT05195918
- Testing
- EGCG 300 mg + Nintedanib, EGCG 300 mg + Pirfenidone, EGCG 600 mg + Nintedanib
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Hal Chapman
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil
Pulmonary Arterial Hypertension (PAH) in the setting of Idiopathic Pulmonary Fibrosis(IPF)is a risk factor for morbidity and mortality in the peri-lung transplant(LT) setting.
- Conditions
- Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Pulmonary Hypertension
- Trial name
- NCT00625079
- Testing
- sildenafil
- Where
- United States
- Sponsor
- University of California, Los Angeles
Interstitial Lung Disease, Interstitial Pulmonary Fibrosis
Enhancing Physical Activity in Patients With Interstitial Lung Disease
The level of physical activity (PA) has been shown to be an important predictor for morbidity and mortality in patients with chronic respiratory diseases such as COPD and more recently Idiopathic Pulmonary Fibrosis.
- Trial name
- NCT04138173
- Testing
- Tele coaching intervention
- Where
- Belgium
- Volunteers
- 40 people
- Sponsor
- KU Leuven
Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis
Social Distancing During the COVID-19 Pandemic and People Living With Chronic Respiratory Diseases
Social distancing during the COVID-19 pandemic could lead to clinical and functional deterioration of people living with chronic respiratory diseases (CRD).
- Conditions
- Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis, Asthma Chronic
- Trial name
- NCT04693975
- Where
- Brazil
- Volunteers
- 94 people
- Sponsor
- Universidade Estadual de Londrina
Telomere Disease
Low-Dose Danazol for the Treatment of Telomere Related Diseases
Background: DNA is a structure in the body. It contains data about how the body develops and works. Telomeres are found on the end of chromosomes in DNA.
- Trial name
- NCT03312400
- Testing
- Danazol
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Fibrosis, Pulmonary
Inspiratory Effort Assessed Through Nasal Pressure Measurement in Patients With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF) is a fibrosing progressive interstitial lung disease with unknown etiology, with a median survival of 3 years since first diagnosis.
- Trial name
- NASA (NCT05310669)
- Testing
- Nasal pressure assessment
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- University of Modena and Reggio Emilia
COPD (With - Without Rehabilitation), Diffuse Interstitial Lung Diseases
Development of a New Tool for Dyspnea Measurement in Chronic Respiratory Diseases
The purpose of this study is the psychometric validation of a self-administered dyspnea questionnaire, usable in clinical practice in order to assess dyspnea and its impact on patients with chronic respiratory diseases.
- Conditions
- COPD (With - Without Rehabilitation), Diffuse Interstitial Lung Diseases, Pulmonary Arterial Hypertension Primary or Secondary (Post Embolic .....), Cystic Fibrosis of the Adult
- Trial name
- DYSLIM (NCT02229994)
- Testing
- Cross sectional psychometric evaluation of a self-administered dyspnea questionnaire.
- Where
- France
- Volunteers
- 199 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Progressive Fibrosing Interstitial Lung Disease, Lung Transplant
Integrating Electronic Patient Reported Biometric Measures (ePReBMs) From Wearable Devices in Respiratory Diseases
Lung diseases are one of the most common causes of emergency room visits. There are very few tools that are able to predict which patients will have a worsening or increasing severity of their condition.
- Conditions
- Progressive Fibrosing Interstitial Lung Disease, Lung Transplant, Cystic Fibrosis, Bronchiectasis
- Trial name
- NCT04857814
- Testing
- ADAMM- RSM Device
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- University of Alberta
Idiopathic Pulmonary Fibrosis
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Doses of Inhaled CHF10073 in Participants With Idiopathic Pulmonary Fibrosis
The objective of the study is to assess the safety and tolerability of repeated doses of CHF10073 and to characterise cough-related safety outcomes associated with CHF10073 administration.
- Trial name
- NCT07876284
- Testing
- CHF10073 low dose, CHF10073 high dose
- Volunteers
- 18 people
- Sponsor
- Chiesi Farmaceutici S.p.A.